Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name DDR2 act mut
Gene Variant Detail

DDR2 act mut (gain of function)

Relevant Treatment Approaches DDR2 inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 act mut lung non-small cell carcinoma sensitive DDR2 inhibitor Lucitanib Preclinical Actionable In a preclinical study, Lucitanib (E-3810) decreased DDR2 phosphorylation, and inhibited proliferation and induced apoptosis in lung squamous cell carcinoma cells harboring a DDR2 activating mutation in culture (PMID: 24696502). 24696502
Clinical Trial Phase Therapies Title Recruitment Status